TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: **4502** Asset Class: Stock



4-1-1 Dosho-machi, Chuo-Ku

540-8645 Osaka

Fax: +81-6-6204-2880

Web:

http://www.takeda.co.jp

E-mail: -

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

12.2022 02.2023 04.2023 06.2023 08.2023 10.2023

Financial figures, Fiscal year: from 01.04. to 31.03. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 2,397,956,000,000 2,593,642,000,000 2,712,893,000,000 Common stock capital 1,676,345,000,000 1,676,263,000,000 1,668,145,000,000 **Fixed assets** 11,559,794,000,000 10,584,376,000,000 10,199,400,000,000 Equity capital of a company 6,354,671,000,000 5,683,523,000,000 5,177,177,000,000 229,557,000,000 849,695,000,000 966,222,000,000 Cash and cash equivalents Accrued liabilities 183,563,000,000 198,046,000,000 197,605,000,000 Other assets **Current liabilities** 2.481.940.000.000 2.145.730.000.000 1.773.176.000.000

Non-current liabilities		5,121,140,000,000		5,348,766,000,000		5,961,940,000,000
Different income		-		-		-
Other liabilities		204,488,000,000		146,430,000,000		222,040,000,000
Total assets	13,957,750,000,000	13,957,750,000,000	13,178,018,000,000	13,178,018,000,000	12,912,293,000,000	12,912,293,000,000

Balance notes

Prepayments and accrued income

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	49,095	47,347	47,099
Equity ratio	45.53%	43.13%	40.13%
Debt-equity ratio	119.63%	131.84%	149.21%

	41	ᆫ	_	
u	п	n	e	п

	2023	2022	2021
Tax Expense Rate	15.13%	22.77%	-2.71%

TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,027,478,000,000	3,569,006,000,000	3,197,812,000,000
Net income	317,017,000,000	230,059,000,000	376,005,000,000
EBIT	3,139,096,600	2,775,975,800	3,123,742,900
Operating income before taxes	383,720,000,000	317,938,000,000	366,159,000,000
Cash Flow	877,217,000,000	1,021,218,000,000	905,073,000,000
Net interest income	-130,886,000,000	-137,140,000,000	-145,930,000,000
Research and development expenses	633,325,000,000	526,087,000,000	455,765,000,000
Income taxes	58,052,000,000	72,405,000,000	-9,936,000,000
Result from investments in subsidaries, associates and other	-8,630,000,000	-15,367,000,000	76,000,000
Revenues per employee	500,410	459,817	414,163

Board of Directors	
Masami lijima	Chairman of Supervisory Board
Andrew Plump	Member of Supervisory Board
John Maraganore	Member of Supervisory Board
Olivier Jean Bohuon	Member of Supervisory Board
Steven Gillis	Member of Supervisory Board
Constantine Saroukos	Member of Supervisory Board
Emiko Higashi	Member of Supervisory Board
lan Clark	Member of Supervisory Board
Jean-Luc Butel	Member of Supervisory Board
Kimberly Reed	Member of Supervisory Board
Koji Hatsukawa	Member of Supervisory Board
Michel Orsinger	Member of Supervisory Board
Miki Tsusaka	Member of Supervisory Board
Yoshiaki Fujimori	Member of Supervisory Board

Chairman of Managing Board Member of Executive Committee Member of Executive Committee Member of Executive Committee
Member of Executive Committee Member of Executive Committee Member of Executive Committee
Member of Executive Committee Member of Executive Committee
Member of Executive Committee
Member of Executive Committee
Member of Executive Committee